{"url_path":"/sec/bysi/8-k/2026-05-13/body","section_key":"body","section_title":"Body","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1677940/0001171843-26-003344-index.html","accession_number":"0001171843-26-003344","cik":"0001677940","ticker":"BYSI","issuer_name":"BeyondSpring Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1677940/0001171843-26-003344-index.html","primary_entity_key":"0001677940","primary_entity_name":"BeyondSpring Inc."},"word_count":1483,"has_tables":true,"body_markdown":"EX-99.1\n2\nexh_991.htm\nPRESS RELEASE\n\nEdgarFiling\n**EXHIBIT 99.1**\n\n**BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update**\n\n****\n\nAACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability\n\nSEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy\n\nFLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- **BeyondSpring Inc.** (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline.\n\n“Plinabulin continues to demonstrate the ability to enhance both efficacy and tolerability in ADC-based regimens, supporting its positioning as a potential backbone agent across a rapidly evolving treatment landscape,” said Dr. Lan Huang, Co-Founder, Chair, and Chief Executive Officer of BeyondSpring. “Data presented at AACR 2026 further highlights the expanding value of our pipeline and reinforces our strategy of advancing highly differentiated therapies with the potential to address significant unmet medical needs. We believe Plinabulin has the potential to become a foundational combination agent that unlocks the full clinical and commercial value of ADC therapies.”\n\nDr. Huang continued, “At SEED, the advancement of ST-01156, a novel RBM39 molecular glue degrader, into clinical development in oncology indications, coupled with a biomarker-driven approach, underscores the strength and scalability of our RITE3™ platform. These milestones reflect disciplined execution across our portfolio and position us to unlock meaningful long-term value through multiple clinical and strategic partnership opportunities.”\n\n**Recent Clinical Highlights**\n\n**Plinabulin:** Expanding Role as a Potentially Foundational Combination Therapy\n\nAACR 2026 data demonstrated that Plinabulin significantly enhances both efficacy and tolerability of topoisomerase inhibitor–based ADC regimens, with or without immune checkpoint inhibitors\n\nPreclinical findings showed:\nImproved complete response rate and survival outcomes\n\nImproved tolerability\n\nEnhanced CD8+ T cell / Treg ratio - shifting the tumor immune environment from suppression to attack\n\nThese preclinical results suggest Plinabulin’s potential to address key limitations of current ADC therapies, including limited durability and dose-limiting safety concerns, and support Plinabulin’s positioning as a potential backbone agent across a broad range of ADC combination regimens\n\n**SEED Therapeutics:**Advancing precision oncology through molecular glue degraders\n\nST-01156 (RBM39 molecular glue degrader) advanced into Phase 1 clinical development, with the first dose cohort completed\n\nAACR 2026 data demonstrated:\nComplete tumor eradication in a neuroblastoma in vivo model\n\nIdentification of MYC overexpression and CDKN2A/B deletion as potential predictive biomarkers\n\nThis program represents a biomarker-driven precision oncology approach and highlights the productivity of SEED’s proprietary RITE3™ platform for targeted protein degradation\n\n**First Quarter Financial Results****1**\n\nContinuing operations:\n\nR&D expenses were $1.1 million for the three months ended March 31, 2026 compared to $0.9 million for the three months ended March 31, 2025. The $0.2 million increase was primarily driven by increased drug manufacturing activities to prepare for potential future study initiation, partially offset by lower regulatory filing advisory and personnel expenses\n\nG&A expenses were $1.1 million for the three months ended March 31, 2026 compared to $1.7 million for the three months ended March 31, 2025. The $0.6 million decrease was primarily driven by lower personnel and legal advisory expenses\n\nNet loss was $2.4 million for the three months ended March 31, 2026 compared to $2.6 million for the three months ended March 31, 2025\n\nCash, cash equivalents, and short-term investments were $7.9 million as of March 31, 2026\n\nDiscontinued operations:\n\nNet loss was $4.3 million for the three months ended March 31, 2026, compared to net income of $3.8 million for the three months ended March 31, 2025\n\nCurrent assets were $5.3 million as of March 31, 2026\n\nNote 1. As a result of BeyondSpring entering into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED, SEED’s operations met the criteria as discontinued operations under ASC 205-20 for financial reporting purposes.\n\n**About BeyondSpring**BeyondSpring (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company developing first-in-class therapies for cancers with high unmet need. Its lead asset, Plinabulin, has been studied in over 700 cancer patients and is in late-stage development across multiple cancer indications, with results published in The Lancet Respiratory Medicine. Learn more at beyondspringpharma.com.\n\n**About SEED Therapeutics**SEED Therapeutics is a clinical-stage biotechnology company pioneering targeted protein degradation. Its proprietary RITE3™ platform is advancing novel molecular glue degraders across oncology, neurodegeneration, and immunology. SEED collaborates with Eli Lilly and Company and Eisai Co., Ltd., and is advancing its RBM39 degrader into clinical development. Learn more at seedtherapeutics.com.\n\n**Investor Contact:**IR@beyondspringpharma.com \n**Media Contact:**PR@beyondspringpharma.com \n\n**Cautionary Note Regarding Forward-Looking Statements**\nThis press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge, beliefs, and expectations regarding possible future events and are subject to risks, uncertainties, and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all; unexpected results from preclinical studies or clinical trials; the risk that preclinical results may not be predictive of clinical results; delays in, or failure to obtain, regulatory approvals; results that do not meet the Company’s expectations regarding the safety, efficacy, clinical utility, or regulatory pathway of the Company’s product candidates; increased competition in the market; the Company’s ability to meet Nasdaq’s continued listing requirements; and other risks described in BeyondSpring’s most recent Form 10-K and subsequent filings with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release, and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.\n\nFinancial Tables to Follow\n\n \n\n**BEYONDSPRING INC.CONDENSED CONSOLIDATED BALANCE SHEETS(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)**\n\n \n\n \n\n  **As of** \n\n  **December 31, 2025**  **March 31,**\n**2026** \n\n  $  $ \n\n      (Unaudited) \n\n**Assets**        \n\n**Current assets:**        \n\nCash and cash equivalents  7,786   4,036 \n\nShort-term investments  4,775   3,827 \n\nAdvances to suppliers  227   177 \n\nPrepaid expenses and other current assets  71   181 \n\nCurrent assets of discontinued operations  8,023   5,283 \n\nTotal current assets  20,882   13,504 \n\n         \n\n**Noncurrent assets:**        \n\nProperty and equipment, net  166   152 \n\nOperating right-of-use assets  305   240 \n\nOther noncurrent assets  224   126 \n\nNoncurrent assets of discontinued operations  4,356   4,384 \n\nTotal noncurrent assets  5,051   4,902 \n\n         \n\n**Total assets**  25,933   18,406 \n\n         \n\n**Liabilities and equity**        \n\n         \n\n**Current liabilities:**        \n\nAccounts payable  363   646 \n\nAccrued expenses  938   1,278 \n\nCurrent portion of operating lease liabilities  320   246 \n\nOther current liabilities  822   937 \n\nCurrent liabilities of discontinued operations  11,133   9,263 \n\nTotal current liabilities  13,576   12,370 \n\n         \n\n**Noncurrent liabilities:**        \n\nDeferred revenue  28,600   28,994 \n\nOther noncurrent liabilities  3,981   4,239 \n\nNoncurrent liabilities of discontinued operations  3,766   3,157 \n\nTotal noncurrent liabilities  36,347   36,390 \n\n         \n\n**Total liabilities**  49,923   48,760 \n\n         \n\n         \n\n         \n\n**Shareholders**’**deficit**        \n\nOrdinary shares ($0.0001 par value; 500,000,000 shares authorized; 41,122,320 and 41,119,820 shares issued and outstanding as of December 31, 2025 and March 31, 2026)  4   4 \n\nAdditional paid-in capital  375,664   375,739 \n\nAccumulated deficit  (408,431)  (410,590)\n\nAccumulated other comprehensive income  602   360 \n\n         \n\nTotal BeyondSpring Inc.’s shareholders’ deficit  (32,161)  (34,487)\n\nNoncontrolling interests  8,171   4,133 \n\nTotal shareholders’ deficit  (23,990)  (30,354)\n\n         \n\n**Total liabilities and shareholders**’**deficit**  25,933   18,406 \n\n \n\n**BEYONDSPRING INC.CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)(Amounts in thousands of U.S. Dollars (“$”), except for number of shares and per share data)(Unaudited)**\n\n \n\n  **Three months ended March 31,** \n\n  **2025**  **2026** \n\n  $  $ \n\n         \n\n**Revenue**  -   - \n\n         \n\n**Operating expenses**        \n\nResearch and development  (874)  (1,076)\n\nGeneral and administrative  (1,736)  (1,156)\n\n         \n\n**Loss from operations**  (2,610)  (2,232)\n\nForeign exchange gain, net  29   50 \n\nInterest income  17   8 \n\nOther income, net  -   15 \n\n         \n\n**Loss before income tax**  (2,564)  (2,159)\n\nIncome tax expenses  (20)  (192)\n\n         \n\n**Net loss from continuing operations**  (2,584)  (2,351)\n\n         \n\n**Discontinued operations**        \n\nLoss from discontinued operations  (3,232)  (4,323)\n\nGain on sale of subsidiary interests  6,986   - \n\nIncome tax expenses  -   - \n\n**Net income (loss) from discontinued operations**  3,754   (4,323)\n\n         \n\n**Net income (loss)**  1,170   (6,674)\n\nLess: Net loss attributable to noncontrolling interests from continuing operations  (75)  (132)\n\nLess: Net loss attributable to noncontrolling interests from discontinued operations  (3,232)  (4,383)\n\n**Net income (loss) attributable to BeyondSpring Inc.**  4,477   (2,159)\n\n         \n\n**Earnings (loss) per share, basic and diluted**        \n\nContinuing operations  (0.06)  (0.05)\n\nDiscontinued operations  0.17   - \n\nBasic and diluted earnings (loss) per share  0.11   (0.05)\n\n         \n\nWeighted-average shares outstanding        \n\nBasic and diluted  40,316,320   41,119,803 \n\n         \n\n**Other comprehensive loss, net of tax of nil:**        \n\nForeign currency translation adjustment loss from continuing operations  (151)  (379)\n\nForeign currency translation adjustment loss from discontinued operations  (7)  (47)\n\n**Comprehensive income (loss)**  1,012   (7,100)\n\nLess: Comprehensive loss attributable to noncontrolling interests from continuing operations  (130)  (269)\n\nLess: Comprehensive loss attributable to noncontrolling interests from discontinued operations  (3,238)  (4,430)\n\n**Comprehensive income (loss) attributable to BeyondSpring Inc.**  4,380   (2,401)"}